ORAL PRESENTATION



Open Access

Augmentation of donor-derived Tax-specific CTL responses by a novel Tax epitope-specific CD4+ helper T-cells in ATL patients after allogeneic hematopoietic stem cell transplantation

Atsuhiko Hasegawa^{1*}, Yotaro Tamai¹, Ayako Takamori¹, Amane Sasada¹, Ryuji Tanosaki², Ilseung Choi³, Atae Utsunomiya⁴, Yasuhiro Maeda⁵, Yoshihisa Yamano⁶, Tetsuya Eto⁷, Ki-Ryang Koh⁸, Hirohisa Nakamae⁸, Youko Suehiro³, Koji Kato⁹, Shigeki Takemoto¹⁰, Jun Okamura¹¹, Naokuni Uike³, Mari Kannagi¹

From 16th International Conference on Human Retroviruses: HTLV and Related Viruses Montreal, Canada. 26-30 June 2013

Adult T-cell leukemia/ lymphoma (ATL) is an aggressive T-cell malignancy caused by human T-cell leukemia virus type 1 (HTLV-1) and characterized by extremely poor prognosis because of intrinsic drug resistance to cytotoxic agents. Recently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been shown to be an effective treatment for ATL due to graft-versus-leukemia effects. However, donor-derived HTLV-1-specific T-cell responses in ATL patients after allo-HSCT are not well understood. In this study, blood samples from 15 ATL patients at 180 days following allo-HSCT from seronegative donors were screened for IFN-g production of donor-derived T-cells against Tax protein. Among 15 patients, Tax-specific T-cell responses were observed in 11 patients. Direct detection with Tax/MHC class I tetramers revealed that donor-derived Tax-specific CD8⁺ cytotoxic T-lymphocytes (CTLs) were present in 12 of 15 patients. We then identified a novel Tax epitope (Tax155-167) presented by HLA-DR1 (HLA-DRB1*0101) and examined the presence of Tax-specific CD4⁺ T-cells in 3 HLA-DR1⁺ patients after allo-HSCT using a newly generated Tax155-167/HLA-DR1 tetramer. Tax155-167specific CD4⁺ T-cells were found to be present in all HLA-DR1⁺ patients tested. Furthermore, in vitro stimulation of PBMCs from HLA-DR1⁺ HLA-A*2402⁺ patients with both Tax155-167 and HLA-A*2402-restricted CTL

epitope (Tax301-309) led to robust expansion of Tax301-309-specific CTLs. Our results suggest that donor-derived HTLV-1-specific both CD4⁺ and CD8⁺ T-cells could be induced in ATL patients after allo-HSCT from seronegative donors, probably due to exposure to HTLV-1 antigens from recipient-derived ATL cells, and the HTLV-1-specific CD4⁺ T-cells may contribute to efficient induction of donor-derived HTLV-1-specific CTL responses.

Authors' details

¹Department of Immunotherapeutics, Tokyo Medical and Dental University, Tokyo, Japan. ²Clinical Laboratories Division, National Cancer Center Hospital, Tokyo, Japan. ³Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan. ⁴Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. ⁵Division of Hematology, Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan. ⁶Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University Graduate School of Medicine, Kawasaki, Japan. ⁷Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan. ⁸Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan. ⁹Department of Medicial Sciences, Fukuoka, Japan. ¹⁰Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan. ¹¹Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan.

Published: 7 January 2014

doi:10.1186/1742-4690-11-S1-O35

Cite this article as: Hasegawa *et al.*: Augmentation of donor-derived Tax-specific CTL responses by a novel Tax epitope-specific CD4+ helper T-cells in ATL patients after allogeneic hematopoietic stem cell transplantation. *Retrovirology* 2014 **11**(Suppl 1):O35.



© 2014 Hasegawa et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*} Correspondence: hase.impt@tmd.ac.jp

¹Department of Immunotherapeutics, Tokyo Medical and Dental University, Tokyo, Japan

Full list of author information is available at the end of the article